Atorvastatin for Renoprotective Effects in contrast-induced NephropAthy preventio

Phase 3

• Conditions: Patients with chronic kidney disease stage 3- 4 undergoing elective coronary angiography; chronic kidney disease; coronary angiography; statin; contrast- induced nephropathy; acute kidney injury

• Registration Number: TCTR20180816001
• Lead Sponsor: Ratchadapisek Somphot Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-08-16
• Study Completion: 2019-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 257

Inclusion Criteria

- 18-80 years old
- Undergoing elective coronary angiography
- eGFR (within 3 months) 15-60 mL/min/1.73 m2

Exclusion Criteria

- Acute coronary syndrome
- Have an indication for high-dose statin e.g. coronary artery disease, cerebrovascular disease
- AST or ALT > 3 times of normal limits
- CPK > 500 U/

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Contrast-induced nephropathy 72 hours Serum creatinine

Secondary Outcome Measures

Name	Time	Method
Change in urine NGAL 6 hours Urine NGA